# Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

> **NCT00092924** · PHASE2 · COMPLETED · sponsor: **Human Genome Sciences Inc.**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** TRAIL-R1 mAb (TRM-1;HGS-ETR1)

## Key facts

- **NCT ID:** NCT00092924
- **Lead sponsor:** Human Genome Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2005-01
- **Final completion:** 2005-03
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092924, "Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00092924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*